# Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

> **NCT00857623** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 127 (actual)

## Conditions studied

- Pain
- Diabetic Neuropathy

## Interventions

- **DRUG:** AZD2066
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00857623
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2012-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857623, "Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00857623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*